Literature DB >> 17517055

Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-gamma production by human mononuclear cells.

X Chen1, M A O'DONNELL, Y Luo.   

Abstract

Successful bacille Calmette-Guérin (BCG) immunotherapy of bladder cancer depends on the proper induction of a T helper-type 1 (Th1) immune response. In this study we investigated the possible involvement of Th1-stimulating cytokines in BCG-induced interferon (IFN)-gamma production as well as their potential roles in enhancing BCG-induced IFN-gamma from human peripheral blood mononuclear cells (PBMCs). BCG efficiently induced IFN-gamma production by PBMCs in a dose-dependent manner. Neutralization of endogenous cytokines interleukin (IL)-2, IL-12 and IFN-alpha reduced BCG-induced IFN-gamma by 38%, 67% and 49%, respectively. Although single recombinant (r) IL-2, rIL-12 and rIFN-alpha induced no or a marginal amount of IFN-gamma, a combination of any two or three cytokines increased IFN-gamma production. When BCG (a subsaturated dose) was combined with mono, dual or triple cytokines, a synergy on IFN-gamma production was observed. Such a synergy was readily achievable even when minimal or low doses of cytokines were used. No saturation of IFN-gamma production was observed even when a subsaturated BCG dose was combined with very high doses of cytokines. A robust IFN-gamma production was also observed when a minimal BCG dose was combined with minimal doses of triple cytokines. In addition, we demonstrated that IL-2- and IFN-alpha-expressing rBCGs were superior to wild-type BCG for PBMC IFN-gamma induction and that combination of both rBCGs showed a synergy in IFN-gamma production. Taken together, these results suggest that combination of BCG with certain exogenous or endogenous (expressed by rBCGs) Th1-stimulating cytokines is a rational candidate for further study in bladder cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17517055      PMCID: PMC1942034          DOI: 10.1111/j.1365-2249.2007.03413.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  45 in total

1.  Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall.

Authors:  S Prescott; K James; T B Hargreave; G D Chisholm; J F Smyth
Journal:  J Urol       Date:  1992-06       Impact factor: 7.450

2.  Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guerin.

Authors:  E C De Boer; W H De Jong; P A Steerenberg; A P Van der Meijden; L A Aarden; F M Debruyne; E J Ruitenberg
Journal:  In Vivo       Date:  1991 Nov-Dec       Impact factor: 2.155

3.  Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy.

Authors:  A Böhle; C Nowc; A J Ulmer; J Musehold; J Gerdes; A G Hofstetter; H D Flad
Journal:  J Urol       Date:  1990-07       Impact factor: 7.450

Review 4.  Long-term results of intravesical therapy for superficial bladder cancer.

Authors:  D L Lamm
Journal:  Urol Clin North Am       Date:  1992-08       Impact factor: 2.241

Review 5.  Interleukin-12. Opportunities for the treatment of bladder cancer.

Authors:  S K Clinton; E Canto; M A O'Donnell
Journal:  Urol Clin North Am       Date:  2000-02       Impact factor: 2.241

6.  Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.

Authors:  E C de Boer; W H de Jong; A P van der Meijden; P A Steerenberg; F Witjes; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1991

7.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

8.  BCG therapy in superficial bladder tumours--complications and precautions.

Authors:  A Steg; S Adjiman; B Debré
Journal:  Eur Urol       Date:  1992       Impact factor: 20.096

9.  Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.

Authors:  E C De Boer; W H De Jong; A P Van Der Meijden; P A Steerenberg; J A Witjes; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

10.  Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials.

Authors:  R De Jager; P Guinan; D Lamm; O Khanna; S Brosman; J De Kernion; R Williams; C Richardson; L Muenz; D Reitsma
Journal:  Urology       Date:  1991-12       Impact factor: 2.649

View more
  8 in total

Review 1.  Future directions in bladder cancer immunotherapy: towards adaptive immunity.

Authors:  Sean G Smith; David A Zaharoff
Journal:  Immunotherapy       Date:  2016-02-09       Impact factor: 4.196

Review 2.  Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.

Authors:  Yi Luo; Jonathan Henning; Michael A O'Donnell
Journal:  Clin Dev Immunol       Date:  2011-09-15

3.  BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi.

Authors:  Maeve K Lalor; Sian Floyd; Patricia Gorak-Stolinska; Anne Ben-Smith; Rosemary E Weir; Steven G Smith; Melanie J Newport; Rose Blitz; Hazzie Mvula; Keith Branson; Nuala McGrath; Amelia C Crampin; Paul E Fine; Hazel M Dockrell
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

4.  Development and application of an interaction network ontology for literature mining of vaccine-associated gene-gene interactions.

Authors:  Junguk Hur; Arzucan Özgür; Zuoshuang Xiang; Yongqun He
Journal:  J Biomed Semantics       Date:  2015-01-06

5.  Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer.

Authors:  Renate Pichler; Georg Gruenbacher; Zoran Culig; Andrea Brunner; Dietmar Fuchs; Josef Fritz; Hubert Gander; Andrea Rahm; Martin Thurnher
Journal:  Cancer Immunol Immunother       Date:  2016-12-22       Impact factor: 6.968

6.  Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins.

Authors:  Marcia R Saban; Helen L Hellmich; Cindy Simpson; Carole A Davis; Mark L Lang; Michael A Ihnat; Michael A O'Donnell; Xue-Ru Wu; Ricardo Saban
Journal:  BMC Cancer       Date:  2007-11-02       Impact factor: 4.430

7.  BCG-induced dendritic cell responses and suppression of interleukin-5 production from T cells in atopic asthmatics.

Authors:  Inseon S Choi; Xiang-Hua Lin; Young-Ah Koh; Yong Cui
Journal:  J Korean Med Sci       Date:  2008-08       Impact factor: 2.153

8.  Combined in vitro IL-12 and IL-15 stimulation promotes cellular immune response in dogs with visceral leishmaniasis.

Authors:  Sidnei Ferro Costa; Vinícius Oliveira Gomes; Marilene Oliveira Dos Santos Maciel; Larissa Martins Melo; Gabriela Lovizutto Venturin; Jaqueline Poleto Bragato; Gabriela Torres Rebech; Catiule de Oliveira Santos; Bárbara Maria Nascimento de Oliveira; Geraldo Gileno de Sá Oliveira; Valéria Marçal Felix de Lima
Journal:  PLoS Negl Trop Dis       Date:  2020-01-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.